Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

107.48 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 Next >
Mirum Pharmaceuticals (NASDAQ:MIRM) Reports Q4 2025 Revenue Beat and 2026 Outlook ↗
Via Chartmill
News headline image
Mirum (MIRM) Q4 2025 Earnings Call Transcript ↗
Mirum (MIRM) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
ACM Research’s AI Surge Collides With Export Controls and Chip Spending Cycles ↗
Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision... 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma. 
Via The Motley Fool
Topics Regulatory Compliance
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Embodies the Minervini Growth Momentum Strategy ↗
Via Chartmill
News headline image
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates. 
Via The Motley Fool
Topics Regulatory Compliance
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Offers a High-Growth Momentum and Technical Breakout Setup ↗
Via Chartmill
News headline image
Is Mirum Pharmaceuticals on a Strong Path to Profitability? ↗
The drugmaker is doing nearly everything else right. 
Via The Motley Fool
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗
Via Chartmill
Mirum Stock Slips On $820M Bluejay Deal — But Wall Street Calls The Hepatitis Drug Seal A 'Steal' ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
Is Mirum Pharmaceuticals About to Soar in 2026? ↗
The future looks bright for this high-flying biotech stock. 
Via The Motley Fool
News headline image
A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM)
Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage... 
Via PredictStreet
Topics Economy Initial Public Offering
News headline image
3 Top Growth Stocks to Buy in the First Half of 2026 ↗
Don't wait too long to make a decision on these three stocks. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 ↗
Focused on rare liver disease therapies, this biopharma company reported a significant insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5 Predictions for the Stock Market in 2026 -- and Which Stocks Will Soar the Most If They're Right ↗
Not all of these predictions may come true. But at least a few of them will likely do so. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now ↗
These predictions were easy. 
Via The Motley Fool
News headline image
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line ↗
Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Prediction: This Stock Has Soared Nearly 70% in 2025 and Will Be an Even Bigger Winner in 2026 ↗
Mirum Pharmaceuticals is a mid-cap biotech stock to keep your eyes on. 
Via The Motley Fool
Topics Earnings
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
A top life sciences investor is doubling down as Aurinia’s flagship therapy gains momentum—here’s what long-term shareholders should watch next. 
Via The Motley Fool
News headline image
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup ↗
Discover MIRM stock: A high-growth biotech with accelerating earnings, strong revenue, and a bullish technical setup poised for a potential breakout. 
Via Chartmill
News headline image
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% ↗
Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock ↗
One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds. 
Via The Motley Fool
News headline image
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge ↗
This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline. 
Via The Motley Fool
News headline image
What Analysts Are Saying About Mirum Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Presents a Compelling Growth Momentum and Technical Setup ↗
Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities. 
Via Chartmill
News headline image
8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup ↗
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout. 
Via Chartmill
News headline image
This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback